Announcements Trials
Browse Landscape

Phase

Phase 2 115Phase 1 32Phase 3 31Phase 1/2 20Phase 4 6Phase NA 3Phase EARLY_PHASE1 2Phase 2/3 2

Status

Active not recruiting 2

Sponsor Class

OTHER_GOV 1INDUSTRY 1

Study Type

Interventional 2

Sponsor

Cancer Type

Genitourinary 2

Conditions

Prostatic Neoplasms 2

Interventions

Cisplatin 98Gemcitabine 66Paclitaxel 62Carboplatin 60Fluorouracil 59Docetaxel 59Capecitabine 59Oxaliplatin 56Cyclophosphamide 54Radiotherapy 50Drug Therapy 46Bevacizumab 38pembrolizumab 35Dexamethasone 33Magnetic Resonance Spectroscopy 32Leucovorin 32Doxorubicin 31Cytarabine 27Etoposide 26Pemetrexed 25Nivolumab 24Methotrexate 24Radiation 20Vincristine 18venetoclax 17apatinib 17Rituximab 17Prednisone 17Letrozole 17Irinotecan 17

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Phase 2/3 × Abiraterone Acetate × Clear all
NCT03706365 2026-04-24

CYCLONE 2

Eli Lilly and Company

Phase 2/3 Active not recruiting
393 enrolled 23 charts
Genitourinary

Prostatic Neoplasms

NCT00268476 2023-04-18

STAMPEDE

Medical Research Council

Phase 2/3 Active not recruiting
11,992 enrolled
Genitourinary

Prostatic Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡